T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS.
Identifieur interne : 002E03 ( PubMed/Corpus ); précédent : 002E02; suivant : 002E04T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS.
Auteurs : Yue-Dan Wang ; Wan-Yee Fion Sin ; Guo-Bing Xu ; Huang-Hao Yang ; Tin-Yau Wong ; Xue-Wen Pang ; Xiao-Yan He ; Hua-Gang Zhang ; Joice Na Lee Ng ; Chak-Sum Samuel Cheng ; Jing Yu ; Li Meng ; Rui-Feng Yang ; Sik-To Lai ; Zhi-Hong Guo ; Yong Xie ; Wei-Feng Chen ; Huang-Hua YangSource :
- Journal of virology [ 0022-538X ] ; 2004.
English descriptors
- KwdEn :
- Amino Acid Sequence, Epitopes, T-Lymphocyte, HLA-A2 Antigen (analysis), Humans, Interferon-gamma (biosynthesis), Membrane Glycoproteins (immunology), Molecular Sequence Data, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Spike Glycoprotein, Coronavirus, T-Lymphocytes (immunology), Viral Envelope Proteins (immunology).
- MESH :
- chemical , analysis : HLA-A2 Antigen.
- chemical , biosynthesis : Interferon-gamma.
- chemical , immunology : Membrane Glycoproteins, Viral Envelope Proteins.
- chemical : Epitopes, T-Lymphocyte, Spike Glycoprotein, Coronavirus.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, T-Lymphocytes.
- Amino Acid Sequence, Humans, Molecular Sequence Data.
Abstract
The immunogenicity of HLA-A2-restricted T-cell epitopes in the S protein of the Severe acute respiratory syndrome coronavirus (SARS-CoV) and of human coronavirus strain 229e (HCoV-229e) was analyzed for the elicitation of a T-cell immune response in donors who had fully recovered from SARS-CoV infection. We employed online database analysis to compare the differences in the amino acid sequences of the homologous T epitopes of HCoV-229e and SARS-CoV. The identified T-cell epitope peptides were synthesized, and their binding affinities for HLA-A2 were validated and compared in the T2 cell system. The immunogenicity of all these peptides was assessed by using T cells obtained from donors who had fully recovered from SARS-CoV infection and from healthy donors with no history of SARS-CoV infection. HLA-A2 typing by indirect immunofluorescent antibody staining showed that 51.6% of SARS-CoV-infected patients were HLA-A2 positive. Online database analysis and the T2 cell binding test disclosed that the number of HLA-A2-restricted immunogenic epitopes of the S protein of SARS-CoV was decreased or even lost in comparison with the homologous sequences of the S protein of HCoV-229e. Among the peptides used in the study, the affinity of peptides from HCoV-229e (H77 and H881) and peptides from SARS-CoV (S978 and S1203) for binding to HLA-A2 was higher than that of other sequences. The gamma interferon (IFN-gamma) release Elispot assay revealed that only SARS-CoV-specific peptides S1203 and S978 induced a high frequency of IFN-gamma-secreting T-cell response in HLA-A2(+) donors who had fully recovered from SARS-CoV infection; such a T-cell epitope-specific response was not observed in HLA-A2(+) healthy donors or in HLA-A2(-) donors who had been infected with SARS-CoV after full recovery. Thus, T-cell epitopes S1203 and S978 are immunogenic and elicit an overt specific T-cell response in HLA-A2(+) SARS-CoV-infected patients.
DOI: 10.1128/JVI.78.11.5612-5618.2004
PubMed: 15140958
Links to Exploration step
pubmed:15140958Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS.</title>
<author><name sortKey="Wang, Yue Dan" sort="Wang, Yue Dan" uniqKey="Wang Y" first="Yue-Dan" last="Wang">Yue-Dan Wang</name>
<affiliation><nlm:affiliation>Department of Immunology, Peking University Health Science Centre, 38, Xueyuanlu, Beijing, 100083, People's Republic of China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sin, Wan Yee Fion" sort="Sin, Wan Yee Fion" uniqKey="Sin W" first="Wan-Yee Fion" last="Sin">Wan-Yee Fion Sin</name>
</author>
<author><name sortKey="Xu, Guo Bing" sort="Xu, Guo Bing" uniqKey="Xu G" first="Guo-Bing" last="Xu">Guo-Bing Xu</name>
</author>
<author><name sortKey="Yang, Huang Hao" sort="Yang, Huang Hao" uniqKey="Yang H" first="Huang-Hao" last="Yang">Huang-Hao Yang</name>
</author>
<author><name sortKey="Wong, Tin Yau" sort="Wong, Tin Yau" uniqKey="Wong T" first="Tin-Yau" last="Wong">Tin-Yau Wong</name>
</author>
<author><name sortKey="Pang, Xue Wen" sort="Pang, Xue Wen" uniqKey="Pang X" first="Xue-Wen" last="Pang">Xue-Wen Pang</name>
</author>
<author><name sortKey="He, Xiao Yan" sort="He, Xiao Yan" uniqKey="He X" first="Xiao-Yan" last="He">Xiao-Yan He</name>
</author>
<author><name sortKey="Zhang, Hua Gang" sort="Zhang, Hua Gang" uniqKey="Zhang H" first="Hua-Gang" last="Zhang">Hua-Gang Zhang</name>
</author>
<author><name sortKey="Ng, Joice Na Lee" sort="Ng, Joice Na Lee" uniqKey="Ng J" first="Joice Na Lee" last="Ng">Joice Na Lee Ng</name>
</author>
<author><name sortKey="Cheng, Chak Sum Samuel" sort="Cheng, Chak Sum Samuel" uniqKey="Cheng C" first="Chak-Sum Samuel" last="Cheng">Chak-Sum Samuel Cheng</name>
</author>
<author><name sortKey="Yu, Jing" sort="Yu, Jing" uniqKey="Yu J" first="Jing" last="Yu">Jing Yu</name>
</author>
<author><name sortKey="Meng, Li" sort="Meng, Li" uniqKey="Meng L" first="Li" last="Meng">Li Meng</name>
</author>
<author><name sortKey="Yang, Rui Feng" sort="Yang, Rui Feng" uniqKey="Yang R" first="Rui-Feng" last="Yang">Rui-Feng Yang</name>
</author>
<author><name sortKey="Lai, Sik To" sort="Lai, Sik To" uniqKey="Lai S" first="Sik-To" last="Lai">Sik-To Lai</name>
</author>
<author><name sortKey="Guo, Zhi Hong" sort="Guo, Zhi Hong" uniqKey="Guo Z" first="Zhi-Hong" last="Guo">Zhi-Hong Guo</name>
</author>
<author><name sortKey="Xie, Yong" sort="Xie, Yong" uniqKey="Xie Y" first="Yong" last="Xie">Yong Xie</name>
</author>
<author><name sortKey="Chen, Wei Feng" sort="Chen, Wei Feng" uniqKey="Chen W" first="Wei-Feng" last="Chen">Wei-Feng Chen</name>
</author>
<author><name sortKey="Yang, Huang Hua" sort="Yang, Huang Hua" uniqKey="Yang H" first="Huang-Hua" last="Yang">Huang-Hua Yang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15140958</idno>
<idno type="pmid">15140958</idno>
<idno type="doi">10.1128/JVI.78.11.5612-5618.2004</idno>
<idno type="wicri:Area/PubMed/Corpus">002E03</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E03</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS.</title>
<author><name sortKey="Wang, Yue Dan" sort="Wang, Yue Dan" uniqKey="Wang Y" first="Yue-Dan" last="Wang">Yue-Dan Wang</name>
<affiliation><nlm:affiliation>Department of Immunology, Peking University Health Science Centre, 38, Xueyuanlu, Beijing, 100083, People's Republic of China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Sin, Wan Yee Fion" sort="Sin, Wan Yee Fion" uniqKey="Sin W" first="Wan-Yee Fion" last="Sin">Wan-Yee Fion Sin</name>
</author>
<author><name sortKey="Xu, Guo Bing" sort="Xu, Guo Bing" uniqKey="Xu G" first="Guo-Bing" last="Xu">Guo-Bing Xu</name>
</author>
<author><name sortKey="Yang, Huang Hao" sort="Yang, Huang Hao" uniqKey="Yang H" first="Huang-Hao" last="Yang">Huang-Hao Yang</name>
</author>
<author><name sortKey="Wong, Tin Yau" sort="Wong, Tin Yau" uniqKey="Wong T" first="Tin-Yau" last="Wong">Tin-Yau Wong</name>
</author>
<author><name sortKey="Pang, Xue Wen" sort="Pang, Xue Wen" uniqKey="Pang X" first="Xue-Wen" last="Pang">Xue-Wen Pang</name>
</author>
<author><name sortKey="He, Xiao Yan" sort="He, Xiao Yan" uniqKey="He X" first="Xiao-Yan" last="He">Xiao-Yan He</name>
</author>
<author><name sortKey="Zhang, Hua Gang" sort="Zhang, Hua Gang" uniqKey="Zhang H" first="Hua-Gang" last="Zhang">Hua-Gang Zhang</name>
</author>
<author><name sortKey="Ng, Joice Na Lee" sort="Ng, Joice Na Lee" uniqKey="Ng J" first="Joice Na Lee" last="Ng">Joice Na Lee Ng</name>
</author>
<author><name sortKey="Cheng, Chak Sum Samuel" sort="Cheng, Chak Sum Samuel" uniqKey="Cheng C" first="Chak-Sum Samuel" last="Cheng">Chak-Sum Samuel Cheng</name>
</author>
<author><name sortKey="Yu, Jing" sort="Yu, Jing" uniqKey="Yu J" first="Jing" last="Yu">Jing Yu</name>
</author>
<author><name sortKey="Meng, Li" sort="Meng, Li" uniqKey="Meng L" first="Li" last="Meng">Li Meng</name>
</author>
<author><name sortKey="Yang, Rui Feng" sort="Yang, Rui Feng" uniqKey="Yang R" first="Rui-Feng" last="Yang">Rui-Feng Yang</name>
</author>
<author><name sortKey="Lai, Sik To" sort="Lai, Sik To" uniqKey="Lai S" first="Sik-To" last="Lai">Sik-To Lai</name>
</author>
<author><name sortKey="Guo, Zhi Hong" sort="Guo, Zhi Hong" uniqKey="Guo Z" first="Zhi-Hong" last="Guo">Zhi-Hong Guo</name>
</author>
<author><name sortKey="Xie, Yong" sort="Xie, Yong" uniqKey="Xie Y" first="Yong" last="Xie">Yong Xie</name>
</author>
<author><name sortKey="Chen, Wei Feng" sort="Chen, Wei Feng" uniqKey="Chen W" first="Wei-Feng" last="Chen">Wei-Feng Chen</name>
</author>
<author><name sortKey="Yang, Huang Hua" sort="Yang, Huang Hua" uniqKey="Yang H" first="Huang-Hua" last="Yang">Huang-Hua Yang</name>
</author>
</analytic>
<series><title level="j">Journal of virology</title>
<idno type="ISSN">0022-538X</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Epitopes, T-Lymphocyte</term>
<term>HLA-A2 Antigen (analysis)</term>
<term>Humans</term>
<term>Interferon-gamma (biosynthesis)</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Molecular Sequence Data</term>
<term>SARS Virus (immunology)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>T-Lymphocytes (immunology)</term>
<term>Viral Envelope Proteins (immunology)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>HLA-A2 Antigen</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Interferon-gamma</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Viral Envelope Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Epitopes, T-Lymphocyte</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>T-Lymphocytes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Amino Acid Sequence</term>
<term>Humans</term>
<term>Molecular Sequence Data</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The immunogenicity of HLA-A2-restricted T-cell epitopes in the S protein of the Severe acute respiratory syndrome coronavirus (SARS-CoV) and of human coronavirus strain 229e (HCoV-229e) was analyzed for the elicitation of a T-cell immune response in donors who had fully recovered from SARS-CoV infection. We employed online database analysis to compare the differences in the amino acid sequences of the homologous T epitopes of HCoV-229e and SARS-CoV. The identified T-cell epitope peptides were synthesized, and their binding affinities for HLA-A2 were validated and compared in the T2 cell system. The immunogenicity of all these peptides was assessed by using T cells obtained from donors who had fully recovered from SARS-CoV infection and from healthy donors with no history of SARS-CoV infection. HLA-A2 typing by indirect immunofluorescent antibody staining showed that 51.6% of SARS-CoV-infected patients were HLA-A2 positive. Online database analysis and the T2 cell binding test disclosed that the number of HLA-A2-restricted immunogenic epitopes of the S protein of SARS-CoV was decreased or even lost in comparison with the homologous sequences of the S protein of HCoV-229e. Among the peptides used in the study, the affinity of peptides from HCoV-229e (H77 and H881) and peptides from SARS-CoV (S978 and S1203) for binding to HLA-A2 was higher than that of other sequences. The gamma interferon (IFN-gamma) release Elispot assay revealed that only SARS-CoV-specific peptides S1203 and S978 induced a high frequency of IFN-gamma-secreting T-cell response in HLA-A2(+) donors who had fully recovered from SARS-CoV infection; such a T-cell epitope-specific response was not observed in HLA-A2(+) healthy donors or in HLA-A2(-) donors who had been infected with SARS-CoV after full recovery. Thus, T-cell epitopes S1203 and S978 are immunogenic and elicit an overt specific T-cell response in HLA-A2(+) SARS-CoV-infected patients.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15140958</PMID>
<DateCompleted><Year>2004</Year>
<Month>06</Month>
<Day>10</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-538X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>78</Volume>
<Issue>11</Issue>
<PubDate><Year>2004</Year>
<Month>Jun</Month>
</PubDate>
</JournalIssue>
<Title>Journal of virology</Title>
<ISOAbbreviation>J. Virol.</ISOAbbreviation>
</Journal>
<ArticleTitle>T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS.</ArticleTitle>
<Pagination><MedlinePgn>5612-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The immunogenicity of HLA-A2-restricted T-cell epitopes in the S protein of the Severe acute respiratory syndrome coronavirus (SARS-CoV) and of human coronavirus strain 229e (HCoV-229e) was analyzed for the elicitation of a T-cell immune response in donors who had fully recovered from SARS-CoV infection. We employed online database analysis to compare the differences in the amino acid sequences of the homologous T epitopes of HCoV-229e and SARS-CoV. The identified T-cell epitope peptides were synthesized, and their binding affinities for HLA-A2 were validated and compared in the T2 cell system. The immunogenicity of all these peptides was assessed by using T cells obtained from donors who had fully recovered from SARS-CoV infection and from healthy donors with no history of SARS-CoV infection. HLA-A2 typing by indirect immunofluorescent antibody staining showed that 51.6% of SARS-CoV-infected patients were HLA-A2 positive. Online database analysis and the T2 cell binding test disclosed that the number of HLA-A2-restricted immunogenic epitopes of the S protein of SARS-CoV was decreased or even lost in comparison with the homologous sequences of the S protein of HCoV-229e. Among the peptides used in the study, the affinity of peptides from HCoV-229e (H77 and H881) and peptides from SARS-CoV (S978 and S1203) for binding to HLA-A2 was higher than that of other sequences. The gamma interferon (IFN-gamma) release Elispot assay revealed that only SARS-CoV-specific peptides S1203 and S978 induced a high frequency of IFN-gamma-secreting T-cell response in HLA-A2(+) donors who had fully recovered from SARS-CoV infection; such a T-cell epitope-specific response was not observed in HLA-A2(+) healthy donors or in HLA-A2(-) donors who had been infected with SARS-CoV after full recovery. Thus, T-cell epitopes S1203 and S978 are immunogenic and elicit an overt specific T-cell response in HLA-A2(+) SARS-CoV-infected patients.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Yue-Dan</ForeName>
<Initials>YD</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, Peking University Health Science Centre, 38, Xueyuanlu, Beijing, 100083, People's Republic of China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Sin</LastName>
<ForeName>Wan-Yee Fion</ForeName>
<Initials>WY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xu</LastName>
<ForeName>Guo-Bing</ForeName>
<Initials>GB</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Huang-Hao</ForeName>
<Initials>HH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wong</LastName>
<ForeName>Tin-yau</ForeName>
<Initials>TY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Pang</LastName>
<ForeName>Xue-Wen</ForeName>
<Initials>XW</Initials>
</Author>
<Author ValidYN="Y"><LastName>He</LastName>
<ForeName>Xiao-Yan</ForeName>
<Initials>XY</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Hua-Gang</ForeName>
<Initials>HG</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ng</LastName>
<ForeName>Joice Na Lee</ForeName>
<Initials>JN</Initials>
</Author>
<Author ValidYN="Y"><LastName>Cheng</LastName>
<ForeName>Chak-Sum Samuel</ForeName>
<Initials>CS</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Jing</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Meng</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Rui-Feng</ForeName>
<Initials>RF</Initials>
</Author>
<Author ValidYN="Y"><LastName>Lai</LastName>
<ForeName>Sik-To</ForeName>
<Initials>ST</Initials>
</Author>
<Author ValidYN="Y"><LastName>Guo</LastName>
<ForeName>Zhi-Hong</ForeName>
<Initials>ZH</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xie</LastName>
<ForeName>Yong</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Wei-Feng</ForeName>
<Initials>WF</Initials>
</Author>
<Author ValidYN="N"><LastName>Yang</LastName>
<ForeName>Huang-Hua</ForeName>
<Initials>HH</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Virol</MedlineTA>
<NlmUniqueID>0113724</NlmUniqueID>
<ISSNLinking>0022-538X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015789">HLA-A2 Antigen</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>82115-62-6</RegistryNumber>
<NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Virol. 2004 Jul;78(14):7861</RefSource>
<Note>Yang Huang-Hua [corrected to Yang Huang-Hao]</Note>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018984" MajorTopicYN="Y">Epitopes, T-Lymphocyte</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015789" MajorTopicYN="N">HLA-A2 Antigen</DescriptorName>
<QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013601" MajorTopicYN="N">T-Lymphocytes</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2004</Year>
<Month>6</Month>
<Day>21</Day>
<Hour>10</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>5</Month>
<Day>14</Day>
<Hour>5</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15140958</ArticleId>
<ArticleId IdType="doi">10.1128/JVI.78.11.5612-5618.2004</ArticleId>
<ArticleId IdType="pii">78/11/5612</ArticleId>
<ArticleId IdType="pmc">PMC415819</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Virol. 2001 Oct;75(20):9741-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11559807</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cancer Res. 2001 Jul 1;61(13):5145-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11431353</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2002 May 1;99(9):3360-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11964304</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2003 Feb 1;170(3):1191-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12538675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2003 Feb 1;170(3):1291-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12538688</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biomol Struct Dyn. 2003 Apr;20(5):635-44</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12643766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2003 Apr 15;36(8):985-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12684910</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 2003 May;77(9):5464-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12692247</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virus Res. 2002 Mar 20;84(1-2):135-49</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11900846</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1992 Nov;191(1):502-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1413524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunother Emphasis Tumor Immunol. 1993 Aug;14(2):94-103</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7506576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Adv Exp Med Biol. 1993;342:339-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8209751</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 1996 May 15;156(10):3882-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8621927</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Virol. 1998 Aug;72(8):6511-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9658094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2003 May 15;348(20):1948-51</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12748314</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood. 2003 Jun 15;101(12):4930-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12576325</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2003 Jul 16;290(3):374-80</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12865379</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Beijing Da Xue Xue Bao. 2003 May 31;35 Suppl:70-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12914223</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Tissue Antigens. 2003 Oct;62(4):285-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12974795</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1982 Jun;119(2):358-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6281979</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Top Microbiol Immunol. 1982;99:165-200</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6178564</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1983 Apr;64 (Pt 4):761-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6300299</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 1990 May 31;345(6274):449-52</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2342577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunogenetics. 1999 Nov;50(3-4):213-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10602881</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Biochim Pol. 2000;47(1):23-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10961675</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E03 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002E03 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Corpus |type= RBID |clé= pubmed:15140958 |texte= T-cell epitopes in severe acute respiratory syndrome (SARS) coronavirus spike protein elicit a specific T-cell immune response in patients who recover from SARS. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15140958" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |